Carelizumab Combined With Regorafenib in the Treatment of HCC（CARE-2020）

Nanfang Hospital, Southern Medical University

Status and phase: Unknown; Phase 2

Conditions: Hepatocellular Carcinoma

Treatments: Drug: Regorafenib Pill&Camrelizumab

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT04806243

NFEC-2021-010

Details and patient eligibility

About

To investigate the efficacy and safety of carelizumab combined with regorafenib in second-line treatment for patients with primary hepatocellular carcinoma.

Full description

Currently, there is little experience in the application of targeted drugs combined with immunotherapy. Through this study, we hope to explore the optimal population for the use of carelizumab combined with regorafenib in the second-line treatment of hepatocellular carcinoma (HCC), as well as the efficacy and safety.

This research is a single-center trials phase II second-line, single arm, explore the clinical outcome of treatment.

Enrollment: 69 estimated patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Not convenient to disclose

Exclusion criteria

• Not convenient to disclose

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

69 participants in 1 patient group

Carelizumab Combined With Regorafenib arm

Experimental group

Treatment:

Drug: Regorafenib Pill&Camrelizumab